Your browser does not support JavaScript or it may be disabled!
 India As It Happens
Rediff Labs will showcase innovative products that rediff is working on behind the scenes.
News   |   Images
Get Realtime News
on your webpage

About 644 results for "ranbaxy lab"

Indian bourses' nod for Sun Pharma-Ranbaxy deal

Sun Pharma-Ranbaxy deal clears a big hurdle, secures NSE & BSE...

NEW DELHI: India's top two stock exchanges have approved the merger of Ranbaxy Lab oratories with Sun Pharmaceutical, clearing at least one regulatory hurdle facing consummation of the country's largest in-bound pharma deal inked four months ago. Times of India, 2 months ago

4 images for ranbaxy lab

Financial Express, 2 days ago
Financial Express, 3 weeks ago
VC Circle, 2 months ago, 2 months ago
Business Standard India

Pharma shares in demand; Healthcare index hits new high

Sun Pharma, Ranbaxy, Dr Reddy's Lab, Lupin, Glenmark, Wockhardt and Cadila Healtchare gained 1-8% on BSE.
 Business Standard1 month ago Health care companies' scrips canter along  Business Standard India6 days ago Pharma co shares in limelight with better Q1 performance  PharmaBiz3 weeks ago Pharma stocks outperform equity benchmarks, rally 2-14%  Moneycontrol.com1 month ago

Hold Ranbaxy Lab; target Rs 750-770: Akshata Deshmukh

Akshata Deshmukh, Chief Strategist-Trading at Networth Stock Broking is of the view that one may hold Ranbaxy Laboratories with a target of Rs 750-770.
 Money Control1 month ago Hold Ranbaxy Labs; target of Rs 615: KRChoksey  Money Control1 month ago Buy Ranbaxy Labs; target of Rs 605: Motilal Oswal  Money Control1 month ago Accumulate Ranbaxy Labs; target of Rs 616: PLilladher  Money Control1 month ago

More exits from Ranbaxy Lab's top management team

With the fresh exits, nearly half of the members who were part of Ranbaxy’s executive committee two years ago will no longer be part of the team. NEW DELHI: Ranbaxy Laboratories' global HR head Sandeep Girotra has stepped down while its president of ...
 Economic Times1 month ago
4 Traders

Sun Pharma's Ranbaxy deal on course, hints at more acquisitions

Sun Pharmaceutical Industries, India's largest drugmaker by market value, said it is in the process of acquiring Ranbaxy Lab from Japan's Daiichi Sankyo, and is open for more acquisitions. "Till the time we are able to integrate Ranbaxy ...
 DNA India1 month ago Sun's Ranbaxy deal on course, hints at more  4 Traders1 month ago

Ranbaxy, Sun Pharma up 6-8% on US FDA nod; analysts bullish

Ranbaxy’s subsidiary Ohm Lab has received drug regulator US Food and Drug Administration's nod for generic version of Novartis’ blood pressure drug Diovan.
 Money Control2 months ago Ranbaxy arm Ohm Lab gets USFDA nod for Valsartan  Myiris2 months ago Ranbaxy gets FDA approval for Novartis's Diovan generic  The Financial Chronicle2 months ago

Ranbaxy Lab allots equity shares

Ranbaxy Laboratories announced that the ESOPs allotment committee of directors has allotted 207,529 equity shares on exercise of stock options under the Employees Stock Option Scheme(s) of the company. The paid-up equity share capital of the company post ...
 Myiris2 months ago
Money Today

Bull run: Almost 450 stocks hit 52-week highs on BSE

A total of 447 stocks touched their 52-week highs on the BSE, including Lupin, Ranbaxy Lab, Strides Arcolab, Sun Pharma, Tata Motors, Tech Mahindra and TVS Motor. The S&P BSE Sensex closed at 25,823.75, down 17.46 points from Wednesday's close, after hitting ...
 Money Today2 months ago

Ranbaxy Lab receives Civil Investigative Demand from United States Department of Justice

The CID is a request for documents and information, and is not an allegation of wrongdoing or demand for compensation. Ranbaxy Laboratories Ltd has announced that the Company has received a Civil Investigative Demand ("CID") from the United States Department ...
 India Infoline4 days ago Ranbaxy Labs. - Receipt of Civil Investigative Demand ("CID"...  SBICAP Securities5 days ago Ranbaxy Labs. - Communication received from the Competition...  SBICAP Securities3 weeks ago

Price cuts announced by NPPA to hit Ranbaxy, Cipla the most

New Delhi|Mumbai: Ranbaxy Labs and Cipla are among the companies which would face the maximum brunt of the new price cuts announced by National Pharma Pricing Authority (NPPA) early this week. The drug pricing regulator capped prices of 43 ...
 Economic Times3 days ago Angel Broking remains neutral on Ranbaxy Labs  MyIris6 days ago Epirus, Ranbaxy win India approval for arthritis drug copy  Moneycontrol.com6 days ago Ranbaxy Laboratories receives direction from CCI  Moneycontrol.com3 weeks ago
Prev | Next
Personalize your Realtimeclose [x]
Add content to your personalized tab - My News
Add upto 6 topics of your interest:
for eg.2g Scam , World
Personalize the tabs display. ( You can add or remove the tabs )
AlertsGet updates on latest news & your favourite topics right in your inbox.Set an Alert|Manage your Alerts


Realtime News

on your Webpage

Add Widget >Get your members hooked!
Get updated on latest news & your favorite topics right in your inbox!
More     Less